Natera, Inc. (NASDAQ:NTRA) is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.68 per share.
Looking ahead, the full year loss are expected at $ 2.55 per share on the revenues of $ 359.49 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 345.00 million ~ $ 365.00 million
Click Here For More Historical Outlooks Of Natera, Inc.
Previous Quarter Performance
Natera, Inc. unveiled loss for the second quarter of $ 0.75 per share, from the revenue of $ 86.47 million. Street analysts expected Natera, Inc. to report loss of $ 0.58 per share on revenue of $ 73.11 million for the second quarter. The bottom line results missed street analysts by $ 0.17 or 29.31 percent, at the same time, top line results outshined analysts by $ 13.36 million or 18.27 percent.
Stock Performance
Shares of Natera, Inc. traded up $ 3.57 or 4.99 percent on Wednesday, reaching $ 75.07 with volume of 574.80 thousand shares. Natera, Inc. has traded high as $ 75.55 and has cracked $ 72.38 on the downward trend
The closing price of $ 75.07, representing a 323.83 % increase from the 52 week low of $ 16.87 and a 5.36 % decrease over the 52 week high of $ 75.55.
The company has a market capital of $ 6.31 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Recent Analyst recommendations
- On 28th September 2020, initiated by Morgan Stanley at Overweight rating, with $ 80.00 target price.
- On 17th September 2020, initiated by SVB Leerink at Outperform rating, with $ 75.00 target price.
Conference Call
Natera, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.natera.com
Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carriers children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mothers blood and a blood sample from the alleged father.
